Latest GlycoVaxyn AG Stories
ZURICH-SCHLIEREN, Switzerland, July 1, 2014 /PRNewswire/ -- GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, today announced the initiation of a Phase 1 clinical
SCHLIEREN, Switzerland, June 15, 2011 /PRNewswire/ -- GlycoVaxyn AG, a leader in the development of conjugate vaccines, today announced that it will host its Second Annual Science Day to discuss challenges and opportunities in vaccine development on June 16-17, 2011, in Cannes, France.
SCHLIEREN, Switzerland, March 5 /PRNewswire/ -- - Proceeds to Facilitate Clinical Development of Lead Conjugate Vaccine GlycoVaxyn, a pioneer in the development of innovative conjugated vaccines, today announced the successful closing of a CHF25 million (ca. US$22 million, EUR17 million) Series B financing.
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.